David Kerr

CBE FMedSci FRCP

Professor of Cancer Medicine

Consultant Physician

In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.

Key publications

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article

Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557

Recent publications

Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer.
Journal article

Rodriguez-Broadbent H. et al, (2017), Int J Cancer, 140, 2701 - 2708
Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.
Journal article

Sveen A. et al, (2017), Genome Med, 9
Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.
Journal article

Purshouse K. et al, (2017), Cold Spring Harb Mol Case Stud, 3
Is sidedness prognostically important across all stages of colorectal cancer?
Journal article

Kerr DJ. et al, (2016), Lancet Oncol, 17, 1480 - 1482
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article

Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557

More publications